Research programme: indolinone derivatives - SUGENAlternative Names: Indolinone derivatives research programme - SUGEN; SU 5614; SU 6577; SU 6663; SU-4984
Latest Information Update: 29 Feb 2008
At a glance
- Originator SUGEN
- Class Small molecules
- Mechanism of Action Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Oct 2000 Preclinical development for Cancer in USA (Unknown route)